Literature DB >> 1282722

Inhibition of sodium-dependent transport systems in LLC-PK1 cells by metabolites of ifosfamide.

M Mohrmann1, A Pauli, M Ritzer, B Schönfeld, B Seifert, M Brandis.   

Abstract

Ifosfamide (IF) is an alkylating cytostatic derived from nitrogen mustard. In addition to its well-known urotoxic effects (hemorrhagic cystitis), several cases of Fanconi syndrome following IF therapy have been reported. No information is available concerning the pathomechanisms of this tubulotoxicity. We used the permanent renal epithelial cell line LLC-PK1 in order to investigate whether major metabolites of IF (i.e. 4-OH-IF, acrolein and chloracetyldehyde) induced the transport defects most frequently detected after IF therapy in vivo. LLC-PK1 cells of passages 162-177, grown in plastic culture dishes, were used in a confluent state. Sodium-dependent and independent fluxes of l-[3H]alanine and of D-[3H]glucose were determined by standard techniques. Activities of marker enzymes of apical and basolateral membranes, of mitochondria and of endoplasmic reticulum were determined in cell homogenates. IF itself has no detectable effect on fluxes of l-alanine and D-glucose in LLC-PK1 cells. The IF metabolite 4-OOH-IF induces a clear inhibition of sodium-dependent fluxes of both substrates after a 24-hour exposure of cells to 100 mumol/l of 4-OOH-IF. Chloracetaldehyde induces a biphasic response of sodium-dependent fluxes of l-alanine with increased uptake rates at low concentrations (< 200 mumol/l) and with a short incubation time, while higher concentrations and long exposure of the cells leads to a reduction in sodium coupled transport. Glucose transport is affected in a comparable way, however, in contrast to alanine transport, chloracetaldehyde also stimulates sodium-independent fluxes of glucose. Acrolein is the most toxic substance tested. It severely damages cell monolayers at concentrations beyond 75 mumol/l. Sodium-coupled glucose and alanine transport is inhibited by acrolein at concentrations higher than 50 mumol/l. Sodium-coupled glucose transport is more sensitive to all metabolites tested than alanine transport. While acrolein strongly affects both transport systems, marker enzymes of the apical plasma membrane, i.e. alkaline phosphatase and leucine amino-peptidase, are not significantly inhibited, suggesting a specificity of the toxic effect for the transport proteins. We conclude that LLC-PK1 cells represent a good model for further investigation of the pathogenesis of Fanconi syndrome after IF therapy. Sodium-dependent transport systems are more sensitive to acrolein than other cell surface proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1282722     DOI: 10.1159/000173465

Source DB:  PubMed          Journal:  Ren Physiol Biochem        ISSN: 1011-6524


  5 in total

1.  Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells.

Authors:  J Springate; K Chan; H Lu; S Davies; M Taub
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-06       Impact factor: 2.416

2.  Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells.

Authors:  Gerald Schwerdt; Nader Gordjani; Andreas Benesic; Ruth Freudinger; Brigitte Wollny; Antje Kirchhoff; Michael Gekle
Journal:  Pediatr Nephrol       Date:  2005-11-03       Impact factor: 3.714

3.  Ifosfamide toxicity in cultured proximal renal tubule cells.

Authors:  James Springate; Mary Taub
Journal:  Pediatr Nephrol       Date:  2006-10-27       Impact factor: 3.714

4.  Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

Authors:  M Mohrmann; S Ansorge; U Schmich; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

5.  Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.

Authors:  M Mohrmann; S Ansorge; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.